The third Bi-Ligand-Drug conjugate CBP-1019 of Coherent Biopharma was granted the FDA's clinical implied licenseon January 18, 202...
The 2022 American Association for Cancer Research (AACR) annual meeting will be held from April 8 to 13, 2022 in New Orleans. Alon...
● The preliminary clinical results showed that CBP-1008 has manageable safety profile. Evident antitumor activity was obser...
Coherent Biopharma’s another BESTTM（Bi-Engaging ligand-mediated Selective Targeting）platform pipeline investigational drug,...